Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAUMACELL – Intravascular Wharton’s Jelly Mesenchymal Stromal Cells for Severe Traumatic Brain Injury
2023-504415-33-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of Wharton's Jelly-derived Mesenchymal Stromal Cells in traumatic brain injury (TBI), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Oct 2023; status: authorised.
02
Drugs
Wharton's Jelly-derived Mesenchymal Stromal Cells
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2023-504415-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504415-33-00.